The spontaneous dominant mouse mutant, Elbow knee synostosis (Eks), shows elbow and knee joint synosotsis, and premature fusion of cranial sutures. Here we identify a missense mutation in the Fgf9 gene that is responsible for the Eks mutation. Through investigation of the pathogenic mechanisms of joint and suture synostosis in Eks mice, we identify a key molecular mechanism that regulates FGF9 signaling in developing tissues. We show that the Eks mutation prevents homodimerization of the FGF9 protein and that monomeric FGF9 binds to heparin with a lower affinity than dimeric FGF9. These biochemical defects result in increased diffusion of the altered FGF9 protein (FGF9 Eks ) through developing tissues, leading to ectopic FGF9 signaling and repression of joint and suture development. We propose a mechanism in which the range of FGF9 signaling in developing tissues is limited by its ability to homodimerize and its affinity for extracellular matrix heparan sulfate proteoglycans.
The fibroblast growth factors (FGFs) are widely expressed in developing and adult tissues and have diverse functions in organogenesis, tissue repair, nervous system control, metabolism and physiological homeostasis 1 . In humans and mice, the 22 FGF ligands are expressed in a spatiotemporally regulated manner and mediate signals through seven different isoforms of FGF receptors (FGFRs) 1 . The pharmacologic potential of FGF ligands has been highlighted by identification of gain-of-function mutations in genes encoding FGFRs 1-3 in individuals with chondrodysplasia and craniosynostosis syndromes 2, 3 . These human diseases identify essential roles of FGF signaling not only in development but also in homeostasis of bones and joints.
Given these clinical, genetic and biochemical studies in humans and mice, the coordinated development of bones and joints seems to rely on precise FGFR signaling. This suggests that spatiotemporal constraints on FGF signaling are a prerequisite for appropriate functions in vivo and are indeed modulated at several distinct levels. First, the expression of FGF ligands is spatiotemporally restricted. Among the 22 FGF ligands, FGF2, FGF4, FGF7, FGF8, FGF9, FGF10, FGF17 and FGF18 are expressed in the limb bud and developing skeleton [4] [5] [6] . Of these, loss-of-function mutations have demonstrated that FGF2, FGF9 and FGF18 are involved in chondrogenesis and/or osteogenesis [7] [8] [9] [10] . Induction of chondrodysplastic phenotypes by overexpression of FGF9 in mice also shows its ability to affect chondrogenesis 11 . Other elements implicated in FGF signaling are the heparan sulfate proteoglycans (HSPGs). Genetic studies in mice and Drosophila melanogaster suggest that HSPGs regulate the distribution and receptor binding of FGF ligands 12, 13 . Finally, structural analyses of FGF9 suggest that it may form homodimers that could affect its ability to signal 14, 15 . Because FGF9 homodimerization occludes several critical receptor binding sites, an autoinhibitory mechanism may function to modulate FGF9-dependent signal transduction. However, a functional demonstration of this proposed mechanism is lacking.
We have previously reported that a dominant mouse mutant, Elbow knee synostosis (Eks), shows radiohumeral and tibiofemoral synostosis, craniosynostosis ( Supplementary Fig. 1 online) and lung hypoplasia 16 . In this study, we identify a missense mutation that replaces Asn143 with threonine in the Fgf9 gene in Eks mutant mice. We designate this mutant allele as Fgf9 Eks and show that this mutation prevents homodimerization of FGF9, consequently decreasing the affinity of FGF9 for heparin. As a result, FGF9 Eks is more diffusible in developing tissues, leading to ectopic FGF9 signaling in the prospective joints and sutures where it functions to repress development. Molecular-dynamics calculations suggest that the reduction in FGF9 affinity for heparin is due to the predominance of the monomeric form rather than to changes in its intrinsic affinity for heparin. We thus propose a mechanism in which the range of FGF9 signaling in developing tissues is limited through regulation of its affinity for HSPGs, which is at least in part controlled by the FGF9 monomerdimer equilibrium. These observations could have far-reaching implications for the pharmacologic manipulation of FGF signaling under a variety of circumstances and in a wide range of tissues.
RESULTS

Eks is caused by a missense mutation in Fgf9
The Eks mutation was mapped between the polymorphic markers D14Mit62 and D14Mit5 on mouse chromosome 14 (ref. 16 ). Among 169 genes located in this interval, Fgf9 seemed a likely candidate for the Eks mutation because FGF9 is a ligand for FGFR2c and FGFR3c 17 and is expressed in the developing limbs, cranial sutures and developing lung 8, 18, 19 . Sequence analysis of Fgf9 cDNA from homozygous Eks mice revealed an A-to-C substitution at position 428, which resulted in the replacement of Asn143 with threonine ( Fig. 1a) . Notably, the Asn143 residue in FGF9 is highly conserved among most FGF proteins ( Fig. 1b) and is predicted to be a critical amino acid residue for homodimerization and receptor binding 14, 15 .
We used a genetic approach to determine whether the N143T substitution in Fgf9 was responsible for the Eks phenotype. We observed a mendelian pattern of inheritance of the mutation among 976 offspring of Eks heterozygous (Fgf9 Eks/+ ) matings, with heterozygous mice showing mild skeletal phenotypes and homozygous Fgf9 Eks/Eks littermates showing severe skeletal phenotypes. The Eks phenotype and the mutation in Fgf9 cosegregated in all cases. The absence of recombination between Eks and Fgf9 among nearly 2,000 meiotic events provides strong evidence that the Eks mutation is allelic with Fgf9. a b Figure 1 Missense mutation in the Fgf9 gene of Eks mice. (a) Nucleotide sequence of the Fgf9 cDNA derived from +/+ and Eks/Eks mice. Eks mutants have an A-to-C substitution at position 428, which results in the replacement of Asn143 with threonine. The Eks missense mutation is indicated by the asterisk, and the corresponding amino acid is shown in purple. (b) Structure-based sequence alignment of human FGFs. The amino acid sequence surrounding the N143T substitution in FGF9 Eks and that of its corresponding domain in other human FGF family proteins are aligned on the basis of sequence identity. The Asn143 residue in FGF9 is highly conserved among most FGF proteins (purple box). The asterisk denotes the site of Eks mutation. (a-f) Defects in early specification of prospective elbow joints in Fgf9 Eks/Eks embryos. Hematoxylin and eosin staining (a,d) and in situ detection of Gdf5 (b,e) and Col2a1 (c,f) in the forelimb buds of Fgf9 +/+ and Fgf9 Eks/Eks embryos at E10.5 and E11.5. In Fgf9 +/+ embryos, there was Gdf5 expression at the prospective elbow joint (e, left), which was demarcated as the gap of Col2a1 expression (f, arrow), at E11.5. In Fgf9 Eks/Eks embryos, there was not Gdf5 expression at the prospective elbow joint (e, right). Scale bars, 100 mm. (g-n) Ectopic osteogenesis at the coronal sutures in Fgf9 Eks/Eks fetuses. Hematoxylin and eosin staining (g,k) and von Kossa staining (h,l) and in situ detection of Spp1 (i,m) and Runx2 (j,n) in the coronal suture of Fgf9 +/+ and Fgf9 Eks/Eks fetuses at E15.5 and E16.5. Note the ectopic ossification in the suture of Fgf9 Eks/Eks at E16.5. fb, frontal bone; pb, parietal bone. Scale bars, 100 mm.
Fgf9 Eks/Eks mice phenocopy Fgfr gain-of-function mutants Eks is a dominant mutation and joint synostosis and premature fusion of sutures have also been reported in mice expressing gain-of-function alleles of Fgfr1 (ref. 20) and Fgfr2c (Fgfr2 C342Y ) 21 . Furthermore, homozygous Fgf9 null mutants (Fgf9 À/À ) show rhizomelia but not joint or suture synostosis 8 . Thus, we hypothesized that Fgf9 Eks encodes a gain-of-function mutation. To test this possibility, we first investigated whether there were phenotypic similarities between Eks mutants and gain-of-function mutants for Fgfr1 and Fgfr2 C342Y . As initiation of elbow joint development was primarily impaired in Fgfr1 gain-offunction transgenic mice 20 , we examined radiohumeral joint development in Fgf9 Eks/Eks mice ( Fig. 2a-f ). Gdf5 (ref. 22) and Col2a1 (ref. 23 ) demarcate the prospective elbow joint and cartilaginous condensation, respectively. Gdf5 expression in the prospective joint space was observed as early as embryonic day E11.5 in Fgf9 +/+ control mice, but was completely absent in Fgf9 Eks/Eks mice ( Fig. 2e) . Analysis of the prospective cartilage revealed a gap of Col2a1 expression at the prospective elbow joint in E11.5 wild-type embryos ( Fig. 2f, left) . The gap of Col2a1 expression was absent in Fgf9 Eks/Eks mice ( Fig. 2f, right) . In summary, ectopic chondrocyte differentiation in the prospective elbow joint of Fgf9 Eks/Eks mice seems very similar to that seen in transgenic mice that ectopically express an activated Fgfr1 kinase domain in the presumptive joint field 20 .
Premature fusion of coronal sutures in Fgfr2 C342Y mice results from excess osteogenic differentiation within the coronal suture mesenchyme 21 . To determine whether Fgf9 Eks/Eks mice had similar histological features, we examined mineralization and the expression of the early osteoblast differentiation markers Spp1 (ref. 24) and Runx2 (ref. 25) in the coronal suture ( Fig. 2g-n) . At E15.5, both wildtype and Fgf9 Eks/Eks mice showed similar coronal suture histology ( Fig. 2g-j) . However, at E16.5 von Kossa staining revealed considerably more overlap of the frontal and parietal bones in Fgf9 Eks/Eks mice compared to Fgf9 +/+ mice (Fig. 2l ). Spp1 expression domains, which demarcate preosteoblasts and osteoblasts, showed wide separation of the frontal and parietal bones in Fgf9 +/+ mice; however, there was overlap in the Fgf9 Eks/Eks mice ( Fig. 2m ). Runx2 is highly expressed in immature osteoblasts at the leading edge of the frontal and parietal bones in Fgf9 +/+ mice (Fig. 2n, left) . In E16.5 Fgf9 Eks/Eks mice, the intensity of Runx2 expression in the coronal suture was lower than in Fgf9 +/+ mice ( Fig. 2n , right), suggesting premature differentiation of the osteoblasts at the presumptive suture. These phenotypes reflect abnormal osteogenic differentiation within the coronal suture mesenchyme and indicate that the defect in suture development occurs before E16.5. Taken together, these observations suggest that the FGF9 Eks altered protein mediates excess FGFR signals within the prospective joints and sutures, preventing joint formation and promoting the fusion of cranial sutures.
The Eks mutation impairs homodimerization of FGF9 The predicted involvement of the Asn143 residue in homodimerization and receptor activation 14, 15 suggests that changes in these processes may account for the apparent gain-of-function activity of the FGF9 Eks altered protein. Homodimerization of FGF9 has been proposed to occlude receptor binding sites and consequently mediate an autoinhibitory mechanism for FGF9 signaling. We thus hypothesized that the Eks mutation might impair the autoinhibition. To test this possibility, we compared the degree of homodimerization of wildtype (FGF9 WT ) and FGF9 Eks proteins by analytical ultracentrifugation. FGF9 WT and FGF9 Eks were expressed in Escherichia coli and purified by column chromatography (Supplementary Methods and Supplementary Fig. 2 online) .
The molecular mass and association constant of FGF9 WT and FGF9 Eks were determined by sedimentation equilibrium centrifugation using the purified recombinant proteins ( Fig. 3a,b ). The estimated average molecular masses of FGF9 WT and FGF9 Eks were 39,264 and 32,929 Da, respectively, whereas the calculated monomeric molecular masses were 20,090 and 20,077 Da, respectively. These data suggest that FGF9 WT primarily exists as a dimer, whereas FGF9 Eks exists in a monomer-dimer equilibrium. The calculated association constants of FGF9 WT and FGF9 Eks were 10.4 mM -1 and 0.119 mM -1 , respectively. We further measured the sedimentation coefficient of FGF9 Eks by sedimentation velocity centrifugation. The overlay plots of c(s)-sedimentation coefficient distributions show that FGF9 WT has a unimodal peak at 3.0 S for a single ideal species, whereas FGF9 Eks has bimodal peaks (2.2 S and 3.1 S) for two ideal species (Fig. 3c,d ). This observation suggests that FGF9 WT is present primarily as a dimer, whereas FGF9 Eks exists primarily as a monomer. These interpretations are consistent with the retarded elution of FGF9 Eks relative to FGF9 WT on a gel filtration column ( Fig. 3e ). Therefore, FGF9 Eks is defective in homodimer formation.
FGF9 Eks mediates less potent signaling via several FGFRs
To examine whether the Eks mutaion altered the binding of FGF9 to FGFRs by impairing the autoinhibitory mechanisms, we compared the ability of FGF9 WT and FGF9 Eks to activate FGFRs by assaying the mitogenic activity of both proteins on BaF3 cells expressing individual FGF receptors 17 . FGFR-expressing BaF3 cell lines were treated with increasing concentrations of purified recombinant FGF9 in the presence of 1 mg/ml heparin. Compared to FGF9 WT , FGF9 Eks showed less activity on cells expressing any of the FGFRs except FGFR3c, where FGF9 Eks showed equivalent activity ( Fig. 4a-g) . To test the ability of heparin to enhance FGF9 activity, we treated the BaF3 cell lines with increasing concentrations of heparin in the presence of 0.2 nM FGF9 WT or FGF9 Eks . FGF9 Eks also showed a decreased heparindependent mitotic response on all FGFRs except FGFR3c, where FGF9 Eks showed higher activity in the presence of high concentrations of heparin ( Fig. 4h -n). Because FGF9 Eks does not mediate excess signaling via FGFRs, other properties of the altered protein must be responsible for the phenotype of the Eks mice.
The Eks mutation lowers FGF9 affinity for heparin The decreased heparin-dependent mitogenic activity of FGF9 Eks suggested that its affinity for heparin may be reduced. Heparin is functionally very similar to heparan sulfate, which is present in most tissues in the form of HSPGs. HSPGs function to modulate FGFR activation directly, by mediating FGF-FGFR interactions, and indirectly, by binding FGF ligands and regulating their diffusion through the extracellular matrix and thus their access to distant FGFRs 1, 12, 13, 26 .
As the gain-of-function property of FGF9 Eks may not involve direct interaction with the FGFRs, we hypothesized that its decreased affinity for heparin might allow increased diffusion and thus bioavailability in tissues. To address this possibility, we first measured FGF9-heparin affinity by heparin affinity chromatography ( Fig. 5a ). FGF9 WT was eluted from heparin-conjugated agarose with 1.50 M NaCl as a single peak. In contrast, most FGF9 Eks was eluted at 1.38 M NaCl and a small fraction eluted at 1.10 M NaCl. We next measured the kinetic constants for the FGF9 Eks -heparin interaction using surface plasmon resonance analysis (Fig. 5b,c and Supplementary Table 1 online). The resulting sensorgrams were used for kinetic parameter determination by globally fitting the experimental data to a 1:1 interaction model. The association rate constant (k a ) of FGF9 Eks was slightly greater than that of FGF9 WT , whereas the dissociation rate constant (k d ) of FGF9 Eks was 18-fold greater than that of FGF9 WT . The dissociation constants (K D ) for FGF9 WT and FGF9 Eks were 0.71 ± 0.02 nM and 5.24 ± 0.03 nM, respectively, representing an 86% decrease in affinity of the FGF9 Eks protein for heparin.
Dimerization of FGF9 confers heparin affinity
The above studies indicate the Fgf9 Eks mutation concurrently affects monomer-dimer equilibrium and affinity for heparin. We thus went on to address whether the N143T substitution directly affects the affinity of FGF9 for heparin or whether it directly affects homodimerization and secondarily affects heparin affinity. However, direct biochemical measurements of the affinity of the two species for heparin are not possible because monomeric and dimeric forms of FGF9 are in equilibrium. We therefore analyzed the configuration of heparin-binding domains in monomeric and dimeric FGF9 using molecular-dynamics simulations and calculated the binding free energy between FGF9 and heparin using the molecular mechanics Poisson-Boltzmann/surface area (MM-PBSA) method. It is well known that the binding free energies calculated by this method show good qualitative but not quantitative agreement with experimental observations 27 .
To model the heparin binding affinity of FGF9, we carried out molecular-dynamics simulations of 2:2 FGF9 WT -heparin and 2:2 FGF9 Eks -heparin complexes based on a 2:2:2 FGF2-FGFR1-heparin crystal structure (Protein Data Bank (PDB) ID: 1FQ9) 28 . The conformations of two heparin oligosaccharides in each complex were influenced by strong electrostatic repulsions, resulting in the exclusion of one heparin oligosaccharide from the complex (data not shown). This analysis suggested that 2:2 FGF9-heparin complexes would be unstable. In contrast, molecular-dynamics simulations of 2:1 FGF9 WT -heparin, 2:1 FGF9 Eks -heparin, 1:1 FGF9 WT -heparin and 1:1 FGF9 Eks -heparin complexes suggested that these complexes are stable ( Fig. 5d-g) . Molecular-dynamics simulations of dimeric FGF9heparin complexes did not show a big difference in heparin-binding free energies for 2:1 FGF9 WT -heparin (dimeric FGF9 WT -heparin) and 2:1 FGF9 Eks -heparin (dimeric FGF9 Eks -heparin) complexes ( Fig. 5d,e ). This is due to the strong interaction between the negatively charged heparin oligosaccharide chain and the array of basic amino acid residues located in the heparin binding site near the groove of the dimer interface in both dimeric complexes. In addition, flexibility of the heparin oligosaccharide chain would help to maintain electrostatic interactions. Similarly, there was little difference in the heparinbinding free energies in 1:1 FGF9 WT -heparin (monomeric FGF9 WTheparin) and 1:1 FGF9 Eks -heparin (monomeric FGF9 Eks -heparin) complexes ( Fig. 5f,g) . This is also due to heparin oligosaccharide chain flexibility, the strong negative charge of the heparin oligosaccharide and the presence of several basic amino acid residues in the heparin binding site. Therefore, the Eks mutation does not seem to influence the heparin binding affinity of either the dimeric or the monomeric FGF9-heparin complex. Because the heparin-binding free energies for dimeric FGF9 (Fig. 5d,e ) were smaller than those for monomeric FGF9-heparin for both FGF9 WT and FGF9 Eks (Fig. 5f,g) , the reduced binding affinity to heparin of the FGF9 Eks protein is most likely due to the shift in the monomer-dimer equilibrium toward the monomer. In summary, the Eks mutation primarily affects homodimerization of FGF9 and only secondarily affects heparin affinity.
FGF9 Eks is potentially hyperdiffusible in tissues
Heparin-FGF2 interactions have previously been shown to regulate the diffusibility of FGF2 (refs. 26, 29) . We hypothesized that the diffusibility of FGF9 Eks in tissues would be increased because of its lower affinity for heparin, leading to ectopic localization outside of the normal signaling domain and, consequently, ectopic activation of FGFRs. However, this model can only be considered if the following two prerequisites are met: first, Fgf9 and Fgfrs are expressed in the proximity of the prospective elbow and knee joints and coronal sutures and, second, the increased diffusibility of FGF9 Eks is dominant over its decreased ability to activate FGFRs.
We first examined the expression of Fgf9 and Fgfr1, Fgfr2 and Fgfr3 in the forelimb buds in E10.5 and E11.5 mice. Fgf9 was expressed in migrating myoblasts, both in Fgf9 +/+ and Fgf9 Eks/Eks mice (Supplementary Fig. 3a,b ,i,j online). At E10.5, Fgfr1, Fgfr2 and Fgfr3 were expressed diffusely in the limb bud mesenchyme, overlapping the expression domain of Col2a1 in both Fgf9 +/+ and Fgf9 Eks/Eks tissues ( Supplementary Fig. 3c-h) . At E11.5, Fgfr1 expression was excluded from the cartilaginous condensation, whereas Fgfr2 and expression was observed mainly in this location ( Supplementary  Fig. 3k-p) . Therefore, mesenchymal cells in the prospective elbow joint express FGFRs. Previous reports showed that Fgf9 is expressed in the developing frontal and parietal bones, particularly strongly at the rims of the bones 18 . Fgfr1, Fgfr2 and Fgfr3 are expressed within and around the developing frontal and parietal bone domains 30 . Thus, the first prerequisite was validated.
FGF9 Eks is able to inhibit joint and suture development To address the second prerequisite for our model, we examined the inhibitory effects of FGF9 WT and FGF9 Eks on joint development by ectopically expressing them in the chicken limb bud using a replication component retroviral vector (RCAS) transduction. RCAS-Fgf9 WT , RCAS-Fgf9 Eks or empty RCAS virus was used to infect the prospective hindlimb bud region in the lateral plate mesoderm. FGF9 WT and FGF9 Eks were expressed throughout the hindlimb buds (Fig. 6a,b ). Ectopic expression of both Fgf9 WT and Fgf9 Eks caused knee joint fusion ( Fig. 6c,d) , whereas no abnormalities were induced by the empty vector ( Fig. 6e) . Therefore, FGF9 Eks retains inhibitory effects on joint development as well as FGF9 WT . It is notable that skeletal defects induced by the expression of FGF9 WT were widespread, whereas those mediated by FGF9 Eks were limited to the prospective joint regions. This is consistent with our finding that FGF9 Eks preferentially activates FGFR3c (Fig. 4) , which is expressed in the bone anlagen ( Supplementary Fig. 3) , whereas FGF9 WT is expected to activate all of the mesodermally expressed FGFRs.
To examine the inhibitory effects of FGF9 WT and FGF9 Eks on suture development, we implanted FGF9-soaked AffiGel-Blue beads in the coronal suture of normal mouse fetal skulls around the initiation stage of the suture defect, at E15, by ex utero surgery. We first confirmed that approximately equal amounts of FGF9 WT and FGF9 Eks were loaded in each AffiGel-Blue bead and that the diffusion rates of FGF9 WT and FGF9 Eks from the beads were almost identical (Supplementary Fig. 4 online) . The expression of Spp1, an early osteoblast differentiation marker upregulated by FGF9, was examined 24 h after in utero bead placement. Grafts of FGF9 WT and FGF9 Eks beads also promoted ectopic Spp1 expression at the leading edges of the frontal and parietal bones ( Fig. 6f-i) . This FGF9-induced ectopic expression of Spp1 resembled that observed in the Fgf9 Eks/Eks coronal suture (Fig. 2m, right) . Therefore, ectopic expression of either FGF9 Eks or FGF9 WT within the suture inhibits suture development.
FGF9 Eks is more diffusible than FGF9 WT in developing tissues
To examine whether the diffusibility of FGF9 Eks in mesenchymal tissue is increased in comparison with FGF9 WT , we measured the diffusibility of FGF9 WT and FGF9 Eks in the skull following bead implantation ( Fig. 7a-e ). Because FGF9 upregulates Spp1 expression, we could measure the area of high Figure 7 Ectopic FGF9 Eks signaling due to its hyperdiffusibility. (a-e) Increased diffusibility of FGF9 Eks in the skull bone anlagen. FGF9 WT or FGF9 Eks beads were implanted onto the coronal suture at E15 mice and Spp1 expression was examined by whole-mount in situ hybridization 24 h after implantation. On the operated sides with FGF9 WT (a) and FGF9 Eks (c) bead implants, we observed well-defined intense signals in the frontal and parietal bone anlagen around the implants, which were not seen on the unoperated side (b,d). This domain with intense Spp1 signals reflects diffusibility of exogenous FGF9 proteins. We therefore compared diffusibility of FGF9 WT and FGF9 Eks based on the induced expression domain of Spp1 (e). The diffusion areas (%) in the frontal and parietal bone anlagen area were estimated from the area ratio of the intense Spp1 expression against the frontal and parietal bone anlagen. Data are represented as mean ± s.e.m. of six operations. FGF9 Eks is more diffusible than FGF9 WT . Significance was determined by two-tailed Student's t-test. the distance over which FGF9 exerts its effects. Implantation of FGF9 Eks beads resulted in a larger area of Spp1 expression (high Spp1 expression area / Frontal and parietal bone anlagen area ¼ 82.9 ± 7.3%) (± s.e.m.) compared with beads loaded with FGF9 WT (50.7 ± 4.4%; P ¼ 0.0035), suggesting that the altered protein diffused more effectively through the developing tissue. Next, we investigated the diffusibility of FGF9 Eks in forelimb buds. FGF9 WT -or FGF9 Eks -soaked AffiGel-Blue beads were grafted into the dorsal and central forelimb bud region of Fgf9 À/À embryos around the initiation stage of the joint defect, at E10.5. FGF9 protein released from the beads into mesenchymal tissue 2 h after implantation was detected by immunohistochemistry using FGF9 antibodies on sections ( Fig. 7f-h) . This analysis showed that FGF9 Eks permeated through the limb bud mesenchyme to a greater extent (relative disffusion area ¼ 138 ± 12%) (± s.e.m.) than FGF9 WT (100 ± 14%; P ¼ 0.043), supporting the hypothesis that FGF9 Eks is more diffusible than FGF9 WT .
Ectopic FGF signaling in the prospective joint of Eks mice
To examine whether diffusion of endogenous FGF9 Eks is increased in comparison to FGF9 WT , we determined the degree of activation of FGFRs in the prospective elbow joint of Fgf9 Eks/Eks mice. As a readout for FGFR signaling, we examined the expression of Etv4 and Etv5, both of which are known to be transcriptionally activated by FGF signaling, in the forelimb buds 31 (Fig. 7i-x) . In wild-type E10.5 limbs, we did not observe the intensive expression of Etv4 or Etv5 within the region undergoing cartilaginous condensation demarcated by Col2a1 expression (Fig. 7m,o) . However, in E10.5 Fgf9 Eks/Eks limbs, we found ectopic expression of both Etv4 and Etv5 in the cartilaginous condensation (Fig. 7n,p) . At E11.5, Etv4 and Etv5 were expressed in the myoblasts and cells surrounding the cartilaginous condensation in wild-type mice (Fig. 7u,w) , whereas in Fgf9 Eks/Eks mice, we observed clear expression of Etv4 and Etv5 in the cartilaginous condensation including the prospective elbow joint position (Fig. 7v,x) . These results demonstrate ectopic FGF signaling in the prospective elbow joint in Fgf9 Eks/Eks mice. Because the ectopic expression domain of Etv4 and Etv5 in Fgf9 Eks/Eks mice was not consistent with the Fgf9 expression domain ( Supplementary Fig. 3a,b ,i,j), this outcome is likely due to increased diffusion of FGF9 Eks protein over a larger area than FGF9 WT .
From these results, we propose a mechanism of elbow joint synostosis in Fgf9 Eks/Eks mice in which FGF9 Eks produced by myoblasts diffuses beyond its normal range and ectopically activates FGFRs in the prospective elbow joint, preventing joint formation (Fig. 7y) . Similarly, FGF9 Eks produced at the rims of the frontal and parietal bones diffuses beyond its normal area and ectopically activates FGFRs in the coronal suture mesenchyme, promoting the fusion of coronal sutures (Fig. 7z) .
Genetic validation of the hyperdiffusible model
A prediction of our model is that the severity of synostotic phenotypes will correlate with a shift in the equilibrium of FGF9 from dimer toward monomer. By molecular-dynamics simulations, we estimated that FGF9 WT homodimer, FGF9 WT/Eks heterodimer and FGF9 Eks homodimer have ten, eight, six intermonomer hydrogen bonds, respectively (Fig. 8a-c and Supplementary Table 2 online). From these results, we calculated the binding free energy of the FGF9 WT/Eks heterodimer to be between those of the FGF9 WT and FGF9 Eks homodimers (Fig. 8a-c ), suggesting that FGF9 WT/Eks heterodimers are more stable than FGF9 Eks homodimers. If our model is correct, FGF9 WT should interfere with FGF9 Eks action by forming FGF9 WT/Eks heterodimers. In other words, skeletal phenotypes due to the Eks mutation should be alleviated by the expression of FGF9 WT .
We first sought experimental evidence that the FGF9 WT/Eks heterodimer was substantially more stable than the FGF9 Eks homodimer. We addressed this issue by immunoprecipitation and protein blot analysis after tagging FGF9 WT and FGF9 Eks with Flag or Myc peptides. Flag-FGF9 WT or Flag-FGF9 Eks was overexpressed together with Myc-FGF9 WT or Myc-FGF9 Eks in COS7 cells and the culture supernatants were subjected to the immunoprecipitation and protein blot analysis (Fig. 8d) . We readily detected Flag-FGF9 WT -Myc-FGF9 WT dimers. Flag-FGF9 Eks -Myc-FGF9 WT dimers were detected at lower level; however, Flag-FGF9 Eks -Myc-FGF9 Eks a e f g h c d b Figure 8 FGF9 WT modulates FGF9 Eks action by forming FGF9 WT -FGF9 Eks heterodimers. (a-c) Proposed solution structures for FGF9 WT homodimer (a), FGF9 WT/Eks heterodimer (b) and FGF9 Eks homodimer (c). Amino acid residues contributing to hydrogen bond formation involved in dimerization are drawn in ball-and-stick and space-filling modes. The single-letter amino acid code, residue number and chain code are indicated for each of these residues. Computed binding free energy of each dimer is shown under the respective illustrated structure. Data are represented as mean ± s.d. of energies obtained from 200 molecular-dynamics snapshots in respective molecular-dynamics trajectory. (d) FGF9 WT is capable of forming dimers with FGF9 Eks . The expression of FGF9 WT homodimers, FGF9 WT/Eks heterodimers and FGF9 Eks homodimers was analyzed using immunoprecipitation and protein blots. The expression vectors for FLAG-or Myc-tagged FGF9 WT and FGF9 Eks were transfected into COS7 cells and culture supernatants were subjected to immunoprecipitation and protein blot analysis. (e-h) Less severe elbow joint synostosis in Fgf9 Eks/+ than Fgf9 Eks/-. Forelimbs from Fgf9 +/À , Fgf9 Eks/+ , Fgf9 Eks/and Fgf9 Eks/Eks embryos at E17.5 were stained with Alcian blue and Alizarin red. Synostotic change is restricted to the cartilaginous component in Fgf9 Eks/+ embryos, whereas it is extended to the bony component in Fgf9 Eks/and Fgf9 Eks/Eks embryos. h, humerus; r, radius; u, ulna.
dimers did not form under these conditions. These data suggest that FGF9 WT and FGF9 Eks can form heterodimers that are more stable than FGF9 Eks homodimers.
We finally examined whether the elbow synostosis caused by FGF9 Eks could be alleviated by the expression of FGF9 WT . We thus compared the severity of elbow synostosis in Fgf9 Eks/+ and compound heterozygous mutants (Fgf9 Eks/-) relative to that of Fgf9 +/À and Fgf9 Eks/Eks mice (Fig. 8e-h) . Elbow joint formation was not affected in Fgf9 +/À mice (Fig. 8e) , whereas elbow synostosis in Fgf9 Eks/Eks mice involved both cartilaginous and bony components (Fig. 8h) . In contrast, the synostosis in Fgf9 Eks/+ mice was limited to the cartilaginous component (Fig. 8f) , whereas the involvement of the bony component in Fgf9 Eks/mice was similar to that of Fgf9 Eks/Eks mice (Fig. 8g) . Therefore, elbow synostosis in Fgf9 Eks/is more severe than in Fgf9 Eks/+ . These findings strongly support our model that the monomer-dimer status of FGF9 influences its affinity for HSPGs and, consequently, its distribution in developing tissues.
DISCUSSION
In the present study, we identified a missense mutation in the Fgf9 gene that is responsible for the Eks mutant phenotype, which includes elbow and knee joint synostosis and craniosynostosis. We further demonstrate that the N143T substitution in FGF9 favors formation of the monomeric form of FGF9, which binds to heparin with a lower affinity than dimeric FGF9. The decreased affinity for heparin leads to increased diffusion of the altered protein in developing tissues, resulting in ectopic FGF9 signaling. We propose that regulation of the monomer-dimer equilibrium of FGF9, and potentially of other FGFs, and its affinity for HSPGs is a mechanism that functions to shape FGF9 concentration gradients in developing tissues. We further propose that these biochemical properties of FGF9 restrict its signaling activity to limited skeletal domains. Data presented here and in previous studies indicate that low FGF signaling in the presumptive joint space is necessary for the formation of the joint space and maintenance of an open suture 20, 21 . Common usage of receptor binding and homodimerization sites of FGF9 could be at least in part instrumental for local modulation of FGF9 signaling activity.
Homodimerization is suggested to be a common feature of the FGF9/16/20 subfamily 32 and of FGF2 (refs. 33,34) . It is not known to what extent homodimerization affects the activity of other FGFs. The discovery that a mutation in Fgf9 can affect homodimerization, affinity for heparin and biological activity suggests that pharmacological agents that affect FGF homodimerization could be useful tools to modulate its activity.
METHODS
Detection of a mutation in the Fgf9 gene. To identify the mutation responsible for the Eks mutant phenotype, we surveyed the cDNA sequence of Fgf9 from normal (+/+), heterozygous (Eks/+) and homozygous (Eks/Eks) mice through reverse transcription-PCR (RT-PCR) and direct sequencing of RT-PCR products.
For genotyping of the Eks allele, genomic DNA spanning the Eks mutation was amplified by PCR using specific primers (Supplementary Table 3 online). PCR products were digested with the diagnostic BsrI restriction enzyme. Wildtype mice show two bands of 147 bp and 42 bp, whereas the Eks allele shows one band of 189 bp ( Supplementary Fig. 5 online) .
Skeletal and histological preparations. Bones and cartilage of E17.5 fetuses were stained with Alizarin red and Alcian blue as previously described 35 . For histological preparations, tissues were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned at 5 mm, and stained with hematoxylin and eosin and von Kossa.
In situ hybridization. In situ hybridization of paraffin sections was done as previously described 36 , using radiolabeled antisense RNA for Gdf5 (MGI: 95688), Col2a1 (MGI: 88452), Spp1 (MGI: 98389), Runx2 (MGI: 99829), Fgf9 (MGI: 104723), Fgfr1 (MGI: 95522), Fgfr2 (MGI: 95523), Fgfr3 (MGI: 95524), Etv4 (MGI: 99423) and Etv5 (MGI: 1096867). In situ hybridization after bead implantation in fetal skulls was done as previously described 24 .
FGF9 WT and FGF9 Eks expression and purification. FGF9 WT and FGF9 Eks expression and purification were done as described in Supplementary Methods.
Analytical ultracentrifugation. All analytical ultracentrifuge experiments were done on a Beckman Coulter XL-I analytical ultracentrifuge. We diluted the samples in 25 mM ammonium acetate buffer (pH 5.5) containing 120 mM NaCl. The partial specific volumes were estimated as 0.7317 ml/g (FGF9 WT ) or 0.7322 ml/g (FGF9 Eks ) by SEDNTERP software. All experiments were done at 20 1C and the absorbance wavelength was 280 nm. We carried out sedimentation equilibrium experiments with six channel centerpieces, with loading concentrations of 0.8, 0.4 and 0.2 mg/ml. Data were obtained at 12, 14 and 16 k rpm for FGF9 WT or at 14, 16 and 18 k rpm for FGF9 Eks . A total equilibration time of 16 h was used for each speed with scans taken at 12, 14 and 16 h. We analyzed the sedimentation equilibrium data using the Beckman XL-A/XL-I Data Analysis software. All nine datasets (three speeds, three concentrations) were fitted together by 'self association model' calculation. Sedimentation velocity experiments were carried out with double sector centerpieces. Protein concentrations were 0.4, 0.3 or 0.2 mg/ml. We scanned the absorbance data 100 times every 5 min at 40 k rpm. The measurements data were analyzed by SEDFIT software.
Analytical gel filtration chromatography. Purified FGF9 WT and FGF9 Eks (100 ml of 2 mg/ml) were loaded onto a Superdex75 10/300 GL column (GE Healthcare) equilibrated with a 25 mM ammonium acetate buffer (pH 5.5) containing 120 mM NaCl. The samples were eluted with the same buffer.
Mitogenic assays. The ability of FGF9 WT and FGF9 Eks to transduce signals via FGFRs was analyzed by a mitogenic assay using BaF3 cells expressing specific FGFRs as described previously 17 . We plated 5,000 cells per well in a 96-well assay plate in media containing varying concentrations of FGF9 and heparin (Wako). FGF9 WT or FGF9 Eks were added to each well for a total volume of 200 ml per well. The cells were then incubated at 37 1C for 36 h. We added 1 mCi of [ 3 H]thymidine to each well in 20 ml of media. The cells were harvested after 4 h by filtration through glass fiber paper and the incorporated [ 3 H]thymidine was counted on a Wallac MicroBeta TriLux scintillation counter (PerkinElmer).
Analytical heparin affinity chromatography. We loaded 3 mg of purified FGF9 WT and FGF9 Eks onto a 1 ml HiTrap heparin HP column (GE Healthcare) equilibrated with 25 mM ammonium acetate buffer (pH 5.5) containing 120 mM NaCl. The bound FGF9 WT or FGF9 Eks were eluted with a linear gradient of NaCl (120 mM to 2.0 M) in the same buffer.
Surface plasmon resonance analysis of FGF9-heparin interactions. Surface plasmon resonance analysis for measurements of FGF9 WT -heparin and FGF9 Eks -heparin interactions were done using a BIAcore 3000 instrument (Biacore AB). In order to immobilize heparin (Wako) on the streptavidinconjugated sensor chip SA, 100 mg/ml biotinylated heparin in HBS-EP buffer was injected at a flow rate of 10 ml/min and was immobilized to 63 response units (RU). All measurements were carried out at room temperature, and refractive index errors due to bulk solvent effects were corrected by subtracting responses on the noncoated sensor chip for the FGF9 WT and FGF9 Eks concentrations used. To obtain kinetic data, we injected different concentrations of analytes (FGF9 WT and FGF9 Eks ) in HBS-EP over the heparin sensor chip at a flow rate of 20 ml/min. At the end of each sample injection (120 s), HBS-EP buffer was passed over the sensor surface to monitor the dissociation phase. Following 120 s of dissociation, the sensor surface was regenerated by injection of 5 ml of 1 M NaCl in HBS-EP. We used five different analyte concentrations to determine the kinetic parameters for each interaction. Kinetic parameters were obtained by global fitting of the sensorgrams to a 1:1 model using BIAevaluation software.
Molecular-dynamics simulation. Starting structures of monomeric FGF9 WT , dimeric FGF9 WT , monomeric FGF9 WT -heparin, dimeric FGF9 WTheparin and FGF9 Eks for molecular-dynamics simulations were taken from the PDB (PDB ID: 1IHK) 14 . The structures of monomeric FGF9 Eks , dimeric FGF9 Eks and heterodimeric FGF9 WT/Eks were constructed based on FGF9 WT using molecular modeling software MOE (Chemical Computing Group). A hexasasaccharide (UAP-SGN-IDU-SGN-IDU-SGN) is used as a heparin oligosaccharide. UAP is 1,4-dideoxy-5-dehydro-O2-sulfo-glucuronic acid, SGN is O6-disulfo-glucosamin and IDU is 1,4-dideoxy-O2-sulfoglucuronic acid. For monomeric FGF9 WT -heparin and dimeric FGF9 WTheparin simulations, heparin oligosaccharide was bound to FGF9 WT structures obtained from molecular-dynamics simulations using the molecular docking program GOLD (version 3.0) 37 . In the docking protocol, the standard default setting of GA parameters was used and GoldScore was used as the scoring function. The structures of monomeric FGF9 Eks -heparin and dimeric FGF9 Eks -heparin were built in the same manner as FGF9 WT -heparin complexes. All the starting structures for molecular-dynamics simulations were surrounded by TIP3P water molecules 38 spherically. After energy minimizations, all molecular-dynamics simulations were carried out for 10 ns at 300 K using modified Amber 8.0 (ref. 39) for MDGRAPE3 system 40 . The Amber ff03 force field 41 was adopted, and the simulation time step was set at 1 s. We calculated the binding free energies by the molecular mechanics Poisson-Boltzmann/surface area (MM-PBSA) method 42 using the last 2 ns moleculardynamics trajectories.
Retroviral misexpression. Mouse Fgf9 WT and Fgf9 Eks cDNAs were cloned into the RCASBP(A) vector 43 . The virus solutions were injected into the hind limb bud of chicken embryos at Hamburger-Hamilton stage 17. We examined the expression of mouse Fgf9 transcripts and skeletal changes 2 and 5 d after injection, respectively.
Subcutaneous insertion of FGF9 Eks beads in mouse fetal skulls. AffiGel-Blue beads (BioRad) soaked in 100 mg/ml FGF9 WT or FGF9 Eks were implanted onto E15 mouse skulls by ex utero surgery as previously described 24 Operated heads were collected 24 h later and Spp1 transcripts were detected by whole-mount in situ hybridization. The area of Spp1 expression was measured using NIH image software.
Implantation of FGF9 Eks beads in mouse forelimb buds. AffiGel-Blue beads that had been soaked in 500 mg/ml FGF9 WT or FGF9 Eks were implanted into the dorsal and central region of E10.5 Fgf9 À/À forelimb buds. Limb buds were subsequently cultured for 2 h on Transwell filters (Costar, Coaning) in serum-free medium (BGJb, 2 mg/ml BSA, penicillin (50 units/ ml), streptomycin (50 mg/ml)), in a humid, 37 1C and 5% CO 2 environment. Explants were fixed in 4% paraformaldehyde and embedded in paraffin. Sections through the equator of the bead were analyzed for exogenous FGF9 using goat antibody to FGF9 (R&D Systems) and a cell and tissue staining kit HRP-AEC system (R&D Systems). We analyzed the signal area and intensity using NIH image software.
Immunoprecipitation and protein blot analysis. cDNA fragments encoding the full length mouse FGF9 WT and FGF9 Eks proteins were cloned into the p3xFlag-CMV-14 vector (Sigma-Aldrich) and into the pCMV-Tag3B vector (Stratagene) to allow expression of FGF9 proteins with either C-terminal Myc or 3xFlag tags. These vectors were transfected into COS7 cells, and 48 h later, culture supernatants were incubated with anti-Flag M2 affinity beads (Sigma-Aldrich) for 1 h at RT and washed three times with PBS and then subjected to protein blots with antibody to Flag M2 (Sigma-Aldrich) or antibody to Myc (Upstate). 
Note: Supplementary information is available on the
